ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
January 31 2008 - 6:00AM
PR Newswire (US)
SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX), announced today that data from
preclinical studies of ANX-201, the Company's broad spectrum
antiviral product candidate, has been accepted for presentation at
the Keystone Symposia HIV Pathogenesis Conference, which takes
place March 27-April 1, 2008 in Banff, Alberta. The HIV
Pathogenesis Conference is part of the Keystone Symposia Global
Health Series, which is supported by the Bill & Melinda Gates
Foundation. The poster presentation entitled "The pyrophosphate
analogue thiophosphonoformic acid confers a favorable HIV
resistance profile," is scheduled to be presented on March 30,
2008. The presentation will highlight results of in vitro
infectivity assays that demonstrate a unique resistance profile for
ANX-201 that suggests suppression of resistance to nucleoside
reverse transcriptase inhibitors (NRTIs), a commonly used class of
drugs. The potential clinical benefit of ANX-201 when used as part
of combination therapy with NRTIs in resistant HIV-infected
patients will also be discussed. About ANX-201 ANX-201
(thiophosphonoformic acid) is a pyrophosphate analog and member of
a new class of reverse transcriptase inhibitor (RTI) for treatment
of resistant HIV-infected patients. ANX-201 has shown activity
against HIV drug-resistant clinical isolates in preclinical
studies. The resistance profile of ANX-201 is unique among approved
RTIs and has been shown to resensitize NRTI-resistant viruses. In
preclinical studies, antiretroviral activity of ANX-201 has
demonstrated synergistic activity with NRTIs suggesting potential
clinical benefits of combination therapy. In other preclinical
studies, ANX-201 has shown broad-spectrum antiviral activity
against HIV-1, HIV-2, human and avian influenza viruses, and herpes
simplex viruses 1 and 2 (HSV-1 and HSV-2). About ADVENTRX
Pharmaceuticals ADVENTRX Pharmaceuticals is a biopharmaceutical
research and development company focused on commercializing
proprietary product candidates for the treatment of cancer and
infectious diseases. The Company seeks to improve the performance
and safety of existing treatments by addressing significant
problems, such as drug metabolism and bioavailability, excessive
toxicity and treatment resistance. More information can be found on
ADVENTRX's web site at http://www.adventrx.com/. Forward Looking
Statement ADVENTRX cautions you that statements included in this
press release that are not a description of historical facts are
forward-looking statements that involve risks and assumptions that,
if they materialize or do not prove to be accurate, could cause
ADVENTRX's results to differ materially from historical results or
those expressed or implied by such forward-looking statements.
These risks and uncertainties include, but are not limited to: the
validity of research results; the risk that preclinical results are
not indicative of the success of subsequent clinical trials and
that products will not perform as preclinical data suggests or as
otherwise anticipated; unexpected adverse side effects or
inadequate therapeutic efficacy of ADVENTRX's product candidates
and other uncertainties inherent in the drug development process;
the timing and success of clinical trials; difficulties or delays
in developing, testing, manufacturing, and obtaining regulatory
approval for ADVENTRX's product candidates; the risk that ADVENTRX
will be unable to raise sufficient capital to fund the projects
necessary to meet its anticipated or stated goals and milestones;
and other risks and uncertainties more fully described in
ADVENTRX's press releases and public filings with the Securities
and Exchange Commission. ADVENTRX's public filings with the
Securities and Exchange Commission are available at
http://www.sec.gov/. You are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date when made. ADVENTRX does not intend to update any
forward-looking statement set forth in this press release to
reflect events or circumstances arising after the date on which it
was made. DATASOURCE: ADVENTRX Pharmaceuticals, Inc. CONTACT: Ioana
C. Hone of ADVENTRX Pharmaceuticals, Inc., +1-858-552-0866 Web
site: http://www.adventrx.com/
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024